Stoke Therapeutics Statistics
Want to see STOK full AI Analyst Report?
Stoke Therapeutics (STOK) Stock Statistics & Valuation Metrics
Total Valuation
Stoke Therapeutics has a market cap or net worth of $1.78B. The enterprise value is $1.46B.
- Market Cap
- $1.78B
- Enterprise Value
- $1.46B
Share Statistics
Stoke Therapeutics has 65,406,265 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 65,406,265
- Owned by Insiders
- 27.03%
- Owned by Institutions
- 41.91%
Financial Efficiency
Stoke Therapeutics’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is -5.66%.
- Return on Equity (ROE)
- -0.02
- Return on Assets (ROA)
- -0.02
- Return on Invested Capital (ROIC)
- -5.66%
- Return on Capital Employed (ROCE)
- -0.06
- Revenue Per Employee
- 1.08M
- Profits Per Employee
- -40.50K
- Employee Count
- 170
- Asset Turnover
- 0.44
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Stoke Therapeutics is -7.32. Stoke Therapeutics’s PEG ratio is -0.05.
- PE Ratio
- -7.32
- PS Ratio
- 64.36
- PB Ratio
- 5.38
- Price to FCF
- -8.42
- Price to Operating Cash Flow
- -9.02
- PEG Ratio
- -0.05
Income Statement
In the last 12 months, Stoke Therapeutics had revenue of 184.42M and earned -6.88M in profits. Earnings per share was -0.12.
- Revenue
- 184.42M
- Gross Profit
- 184.42M
- Operating Income
- -20.59M
- Pretax Income
- -6.88M
- Net Income
- -6.88M
- EBITDA
- -5.12M
- Earnings Per Share (EPS)
- -0.12
Cash Flow
In the last 12 months, operating cash flow was -210.31M and capital expenditures -5.41M, giving a free cash flow of -215.72M billion.
- Operating Cash Flow
- -210.31M
- Free Cash Flow
- -215.72M
- Free Cash Flow per Share
- -3.16
Dividends & Yields
Stoke Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -11.88%
- Earnings Yield
- -12.82%
Stock Price Statistics
- Beta
- 1.71
- 52-Week Price Change
- 10.55%
- 50-Day Moving Average
- 26.79
- 200-Day Moving Average
- 30.90
- Relative Strength Index (RSI)
- 58.10
- Average Volume (3m)
- 1.01M
Important Dates
Stoke Therapeutics upcoming earnings date is May 10, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- May 10, 2027
- Ex-Dividend Date
- ―
Financial Position
Stoke Therapeutics as a current ratio of 5.28, with Debt / Equity ratio of 0.85%
- Current Ratio
- 5.28
- Quick Ratio
- 5.28
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 15.88
- Interest Coverage Ratio
- -2287.78
Taxes
In the past 12 months, Stoke Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Stoke Therapeutics EV to EBITDA ratio is -7.05, with an EV/FCF ratio of -7.92.
- EV to Sales
- 60.56
- EV to EBITDA
- -7.05
- EV to Free Cash Flow
- -7.92
- EV to Operating Cash Flow
- -8.12
Balance Sheet
Stoke Therapeutics has $319.19M in cash and marketable securities with $0.00 in debt, giving a net cash position of $319.19M billion.
- Cash & Marketable Securities
- $319.19M
- Total Debt
- $0.00
- Net Cash
- $319.19M
- Net Cash Per Share
- $4.88
- Tangible Book Value Per Share
- $5.16
Margins
Gross margin is 88.52%, with operating margin of -913.12%, and net profit margin of -862.07%.
- Gross Margin
- 88.52%
- Operating Margin
- -913.12%
- Pretax Margin
- -862.07%
- Net Profit Margin
- -862.07%
- EBITDA Margin
- -858.91%
- EBIT Margin
- -863.53%
Analyst Forecast
The average price target for Stoke Therapeutics is $48.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $48.75
- Price Target Upside
- 75.61% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 8
- Revenue Growth Forecast
- -86.28%
- EPS Growth Forecast
- -634.38%
Scores
- Smart Score
- 5
- AI Score
- 57
